Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) shares crossed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $47.99 and traded as low as $46.90. Travere Therapeutics shares last traded at $46.9940, with a volume of 1,329,568 shares trading hands.
Analysts Set New Price Targets
Several research firms have issued reports on TVTX. TD Cowen upped their price objective on shares of Travere Therapeutics from $60.00 to $75.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Evercore set a $78.00 target price on Travere Therapeutics in a research report on Monday, August 10th. Zacks Research upgraded Travere Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday. Leerink Partners reduced their target price on Travere Therapeutics from $78.00 to $67.00 and set an “outperform” rating for the company in a report on Thursday, November 5th. Finally, JPMorgan Chase & Co. decreased their target price on Travere Therapeutics from $90.00 to $86.00 and set an “overweight” rating for the company in a research report on Friday, November 6th. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $72.55.
Get Our Latest Research Report on Travere Therapeutics
Travere Therapeutics Price Performance
The company has a debt-to-equity ratio of 26.72, a quick ratio of 2.95 and a current ratio of 3.00. The company has a market capitalization of $4.51 billion, a PE ratio of -36.43 and a beta of 1.11. The company’s 50-day simple moving average is $54.23 and its 200-day simple moving average is $47.99.
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last announced its earnings results on Monday, November 2nd. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.49). Travere Therapeutics had a negative return on equity of 185.69% and a negative net margin of 18.66%. The business had revenue of $224.56 million for the quarter, compared to analyst estimates of $195.29 million. During the same quarter last year, the company posted $0.28 EPS. Travere Therapeutics’s quarterly revenue was up 36.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Travere Therapeutics, Inc. will post -0.90 earnings per share for the current year.
Insider Activity at Travere Therapeutics
In other Travere Therapeutics news, CEO Eric Dube sold 243,735 shares of Travere Therapeutics stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $53.82, for a total value of $13,117,817.70. Following the transaction, the chief executive officer directly owned 432,886 shares in the company, valued at approximately $23,297,924.52. This trade represents a 36.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider William Rote sold 112,850 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $63.33, for a total value of $7,146,790.50. Following the completion of the transaction, the insider directly owned 98,197 shares in the company, valued at approximately $6,218,816.01. The trade was a 53.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,294,029 shares of company stock worth $79,454,261 in the last ninety days. Company insiders own 4.44% of the company’s stock.
Institutional Investors Weigh In On Travere Therapeutics
A number of institutional investors have recently added to or reduced their stakes in the business. S&CO Inc. purchased a new stake in shares of Travere Therapeutics in the second quarter valued at approximately $3,181,000. Artia Global Partners LP purchased a new position in Travere Therapeutics in the second quarter worth $19,260,000. Bank of America Corp DE purchased a new position in Travere Therapeutics in the second quarter worth $259,527,000. Elmind Capital LP purchased a new position in Travere Therapeutics in the second quarter worth $16,622,606. Finally, Insight Wealth Strategies LLC acquired a new stake in Travere Therapeutics in the third quarter valued at $5,692,000.
Travere Therapeutics Company Profile
Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with an emphasis on kidney and metabolic disorders. The company was formerly known as Retrophin and adopted the Travere Therapeutics name in 2020. Its commercial products include FILSPARI (sparsentan), an oral treatment approved in the United States for adults with primary IgA nephropathy at risk of disease progression, and THIOLA EC (tiopronin), used to help prevent cystine kidney stones in people with cystinuria.
Featured Articles
- Five stocks we like better than Travere Therapeutics
- Keysight Technologies: The Tollbooth on the Technology Superhighway
- Zscaler Got a Boost From Palo Alto, But Now It Has to Deliver.
- Bargain Hunting: Why Off-Price Retail Is Winning
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
